Navigation Links
Sinovac Reports Unaudited First Quarter 2011 Financial Results
Date:5/13/2011

or the same period of 2010. After deducting depreciation of land use rights, amortization of licenses, permits, the gross margin was 63.5% and 77.8% for the first quarter of 2011 and 2010, respectively. The gross profit margin was adversely affected by lower plant utilization in the first quarter of 2011 as reduced demand caused the Company to scale back production.

Selling, general and administrative expenses for the first quarter 2011 were $4.1 million, compared to $3.1 million in the same period of 2010. SG&A expenses as a percentage of first quarter 2011 sales were 87.75%, compared to 69.9% during the first quarter of the prior year.  The SG&A expenses as a percentage of revenue was in line with the increased sales in private pay market in the first quarter of 2011. However, the overall increase was resulted from an increase in selling expenses due to the adding of new sales personnel in the first quarter 2011.

Net research and development expenses for the first quarter 2011 were $2.1 million, compared to $1.1 million in the same period of 2010. The increased R&D expenses in the first quarter of 2011 were primarily related to the continued development of the pipeline vaccines, including the expenses on EV71 vaccine, which has entered the Phase I clinical trial, the trial production of the animal rabies vaccine and mumps vaccine, and other R&D projects.

Depreciation of property, plant and equipment and amortization of license and permits for the first quarter 2011 were $384,000, compared to $250,000 for the same period of last year.  The change compared to 2010 was primarily attributable to the Sinovac Dalian assets acquired in January 2010, with an additional 25% interest acquired in December 2010 for a majority interest of 55%, and Changping facility acquired in February 2010.

Total operating expenses for the first quarter of 2011 were $6.5 million, compared to $4.4 million in the comparative period in
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sinovac Presents at Two Investor Conferences in May 2011
2. Sinovac Files Annual Report on Form 20-F
3. Sinovac Participates in UBS Greater China Healthcare Corporate Day
4. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
5. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
6. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
7. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
8. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
9. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
10. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
11. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... results after the market closes on Thursday, May ... Company will host a conference call with the investment ... Thursday, May 7, 2015 to discuss the ... Interested parties may access the live conference call ...
(Date:4/30/2015)...   Regulus Therapeutics Inc . (NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that it ... ended March 31, 2015 on Thursday, May 7, 2015, ... Regulus will host a conference call and webcast on ... Time to discuss its first quarter 2015 financial results ...
(Date:4/30/2015)... FRANCISCO, April 30, 2015  Nektar Therapeutics (Nasdaq: ... first quarter ended March 31, 2015. ... 2015 were $325.8 million as compared to $262.8 million ... marketable securities at March 31, 2015 includes a $100.0 ... for the first commercial sale of Movantik™(naloxegol) in the ...
Breaking Medicine Technology:IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... the Jefferies 2012 Global Healthcare Conference in New York, NY. ... Presentation date: Monday, June 4, 2012 , Presentation time: 12:30 ... 30-day archive of these presentations will be available at http://ir.avanir.com ...
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... Yorba Linda, CA (PRWEB) May 01, 2015 ... of our genetic makeup and the interplay of genes ... Keeping up with developments can be daunting. , LabRoots, ... sciences and clinical diagnostics professionals, will soon host its ... Genomics. , At BioConference Live Genetics and Genomics ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... 50 years medical research has been vetted through the ... reviewers to determine whether work merits publication. A study ... and their influence on journal editors who are the ... not. "Published research is becoming a more ...
... Small study found technique restored some muscle function for months ... in using gene therapy to restore some muscle function in ... is the first time such a feat has been performed ... at the annual meeting of the American Society of Gene ...
... Poorman or ... ... personality Jim “Poorman” Trenton has the wavefront Lasik procedure with Los Angeles Lasik ... most noted for his work on Loveline the nightly radio talk show on KROQ, which ...
... ... visibility at the management and board level , ... MetricStream, Inc., the market leader in enterprise-wide Governance, ... with AEI, an emerging markets energy infrastructure company, to provide MetricStream’s GRC Platform and ...
... program reduced cardiovascular disease-related medical and hospital costs, ... national company with 30,000 employees, developed the program ... cardiovascular disease when compared to national benchmarks and ... time, the program included a variety of interventions, ...
... for these two diseases? Or does diabetes cause processes in the ... still unclear why diabetics have a higher rate of cancer than ... In order to precisely identify the types of cancer in ... colleagues in Sweden and the United States to carry out the ...
Cached Medicine News:Health News:To publish or not to publish? That is the question 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 3Health News:'Poorman' Has Lasik with Dr. Khanna 2Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:Increased cancer risk of people with type 2 diabetes 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
The interface spatula can be used when irregular interface adherence occurs. By beginning at the point of a dissected edge and sweeping in uniplanar motion towards the area of adherence, the flap can...
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Medicine Products: